Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GMAB NASDAQ:ITCI NYSE:RDY NASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMABGenmab A/S$22.69+5.5%$21.73$17.24▼$27.94$13.80B0.95984,623 shs3.06 million shsITCIIntra-Cellular Therapies$131.87$131.87$70.90▼$131.98$14.05B0.691.57 million shsN/ARDYDr. Reddy's Laboratories$13.62+2.1%$14.87$12.26▼$16.89$11.13B0.291.57 million shs1.20 million shsSRPTSarepta Therapeutics$17.96+10.5%$22.12$10.41▼$144.22$1.60B0.4622.03 million shs16.44 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMABGenmab A/S+5.49%+4.71%+6.78%+17.02%-14.25%ITCIIntra-Cellular Therapies0.00%0.00%0.00%0.00%+79.10%RDYDr. Reddy's Laboratories+1.95%-4.13%-7.82%+1.45%-17.68%SRPTSarepta Therapeutics+10.46%+9.38%-5.62%-50.48%-87.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGMABGenmab A/S3.6895 of 5 stars3.33.00.00.03.80.03.1ITCIIntra-Cellular Therapies0.9704 of 5 stars1.10.00.04.50.01.70.6RDYDr. Reddy's Laboratories1.7588 of 5 stars2.52.01.70.00.60.01.9SRPTSarepta Therapeutics4.6221 of 5 stars4.12.00.04.23.01.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGMABGenmab A/S 2.64Moderate Buy$37.8066.59% UpsideITCIIntra-Cellular Therapies 2.20Hold$118.00-10.52% DownsideRDYDr. Reddy's Laboratories 3.00Buy$16.9524.50% UpsideSRPTSarepta Therapeutics 2.10Hold$44.17145.92% UpsideCurrent Analyst Ratings BreakdownLatest SRPT, GMAB, ITCI, and RDY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/7/2025SRPTSarepta TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$19.008/7/2025SRPTSarepta TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$48.00 ➝ $50.007/29/2025SRPTSarepta TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderweight ➝ Equal Weight$22.007/29/2025SRPTSarepta TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform7/29/2025SRPTSarepta TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Perform ➝ Market Perform$25.00 ➝ $50.007/29/2025SRPTSarepta TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $20.007/29/2025SRPTSarepta TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$15.007/29/2025SRPTSarepta TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell7/29/2025SRPTSarepta TherapeuticsSanford C. BernsteinSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Perform$13.007/29/2025SRPTSarepta TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$30.00 ➝ $37.007/8/2025GMABGenmab A/STruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$45.00 ➝ $46.00(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGMABGenmab A/S$3.12B4.66$1.60 per share14.19$8.04 per share2.82ITCIIntra-Cellular Therapies$680.50M20.64N/AN/A$6.15 per share21.44RDYDr. Reddy's Laboratories$334.26B0.03$1.05 per share12.91$4.94 per share2.76SRPTSarepta Therapeutics$1.90B0.93$2.69 per share6.67$15.99 per share1.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGMABGenmab A/S$1.14B$1.7612.8912.756.5335.11%18.08%14.52%N/AITCIIntra-Cellular Therapies-$139.67M-$0.73N/A694.05N/A-14.07%-9.93%-8.38%N/ARDYDr. Reddy's Laboratories$663M$0.6620.6316.605.3316.99%17.25%11.63%N/ASRPTSarepta Therapeutics$235.24M-$2.69N/A1.64N/A-2.34%-1.04%-0.37%N/ALatest SRPT, GMAB, ITCI, and RDY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025SRPTSarepta Therapeutics$0.89$2.02+$1.13$1.89$530.66 million$611.09 million7/23/2025Q1 25/26RDYDr. Reddy's Laboratories$0.18$0.20+$0.02$0.20$88.27 billion$988.82 million5/9/2025Q4 24/25RDYDr. Reddy's Laboratories$0.20$0.22+$0.02$0.22$83.70 billion$996.17 million5/8/2025Q1 2025GMABGenmab A/S$0.23$0.31+$0.08$0.31$5.17 billion$715.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGMABGenmab A/SN/AN/AN/AN/AN/AITCIIntra-Cellular TherapiesN/AN/AN/AN/AN/ARDYDr. Reddy's Laboratories$0.070.51%N/A10.61%N/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGMABGenmab A/SN/A5.345.32ITCIIntra-Cellular TherapiesN/A7.667.51RDYDr. Reddy's Laboratories0.011.891.36SRPTSarepta Therapeutics1.004.022.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGMABGenmab A/S7.07%ITCIIntra-Cellular Therapies92.33%RDYDr. Reddy's Laboratories3.85%SRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipGMABGenmab A/S1.54%ITCIIntra-Cellular Therapies2.60%RDYDr. Reddy's Laboratories2.00%SRPTSarepta Therapeutics7.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGMABGenmab A/S2,682641.54 million631.66 millionOptionableITCIIntra-Cellular Therapies560106.52 million103.56 millionOptionableRDYDr. Reddy's Laboratories27,811834.90 million818.20 millionOptionableSRPTSarepta Therapeutics1,37298.28 million90.71 millionOptionableSRPT, GMAB, ITCI, and RDY HeadlinesRecent News About These CompaniesSRPT DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – SRPTAugust 7 at 6:59 PM | globenewswire.comSarepta Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 25, 2025 Deadline to file Lead Plaintiff Motion.August 7 at 5:01 PM | globenewswire.comClass Action Filed Against Sarepta Therapeutics, Inc. (SRPT) - August 25, 2025 Deadline to Join – Contact The Gross Law FirmAugust 7 at 4:32 PM | globenewswire.comSarepta Soars on Q2 Earnings & Sales Beat, Resumes Elevidys DeliveriesAugust 7 at 10:32 AM | zacks.comSRPT SHAREHOLDERS: Sarepta Therapeutics Stock Drop Triggers Securities Fraud Class Action -- ...August 7 at 9:22 AM | gurufocus.comSRPT SHAREHOLDERS: Sarepta Therapeutics Stock Drop Triggers Securities Fraud Class Action – Contact BFA Law by August 25 if You Lost Money (NASDAQ:SRPT)August 7 at 8:18 AM | globenewswire.comCautious Outlook on Sarepta Therapeutics Amid Financial Strain and ELEVIDYS ChallengesAugust 7 at 6:37 AM | tipranks.comDecoding Sarepta Therapeutics Inc (SRPT): A Strategic SWOT InsightAugust 6 at 12:39 AM | gurufocus.comSarepta rises on strong quarterly earnings and revenueAugust 6 at 10:09 PM | msn.comSarepta Therapeutics (SRPT) Reports Q2 Earnings: What Key Metrics Have to SayAugust 6 at 8:01 PM | zacks.comSarepta Therapeutics: Hold Rating Amid Financial Gains and Clinical UncertaintiesAugust 6 at 7:39 PM | tipranks.comSarepta Therapeutics (SRPT) Tops Q2 Earnings and Revenue EstimatesAugust 6 at 6:45 PM | zacks.comSarepta Therapeutics (SRPT) Declines Again On EMA Recommendation to Refuse ELEVIDYS Marketing ...August 6 at 6:13 PM | gurufocus.comSarepta Therapeutics (SRPT) Surges on Strong Q2 EarningsAugust 6 at 6:13 PM | gurufocus.comSarepta Therapeutics (SRPT) Declines Again On EMA Recommendation to Refuse ELEVIDYS Marketing Authorization, Securities Class Action Pending – Hagens BermanAugust 6 at 5:56 PM | globenewswire.comSarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate ...August 6 at 5:13 PM | gurufocus.comSarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate ...August 6 at 5:12 PM | gurufocus.comSarepta reportedly hired Trump-linked lobbying firm after gene therapy deathsAugust 6 at 5:08 PM | msn.comSarepta Therapeutics (SRPT) Faces Regulatory and Financial ChallengesAugust 6 at 4:13 PM | gurufocus.comSarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate DevelopmentsAugust 6 at 4:05 PM | businesswire.comRaiffeisen Bank International AG Purchases 16,000 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)August 6 at 5:07 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSRPT, GMAB, ITCI, and RDY Company DescriptionsGenmab A/S NASDAQ:GMAB$22.69 +1.18 (+5.49%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$22.14 -0.55 (-2.43%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Intra-Cellular Therapies NASDAQ:ITCIIntra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.Dr. Reddy's Laboratories NYSE:RDY$13.62 +0.29 (+2.14%) Closing price 08/7/2025 03:59 PM EasternExtended Trading$13.63 +0.02 (+0.11%) As of 08/7/2025 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.Sarepta Therapeutics NASDAQ:SRPT$17.96 +1.70 (+10.46%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$18.07 +0.11 (+0.63%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down Realty Income Rallies Post-Earnings Miss—Here’s What Drove It Don't Mix the Signal for Noise in Super Micro Computer's Earnings Microsoft Stock Gains as Analysts Boost Price Targets Joby Deal Gives Blade New Direction, But Stock Lacks Lift Uber Technologies Is Driving Cash Flow: Ride It Higher for Life How DigitalOcean's Focus Is Fueling Explosive Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
